Acute Bacterial Skin and Skin Structure Infection Market Research Report By Infection Type (Cellulitis, Erysipelas, Impetigo, Folliculitis, Abscess), By Pathogen (Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Enterobacteriaceae, Anaerobes), By Treatment Setting (Outpatient, Inpatient, Emergency Department), By Mechanism of Action (Penicillins, Cephalosporins, Macrolides, Lincosamides, Fluoroquinolones), By Route of Administration (Oral, Intravenous, Topical) and By Regional (North America, Europe, South America, Asi

Global Acute Bacterial Skin and Skin Structure Infection Market Overview

As per MRFR analysis, the acute bacterial skin and skin structure infection market Size was estimated at 6.15 (USD Billion) in 2022. 

The acute bacterial skin and skin structure infection market is expected to grow from 6.42 (USD Billion) in 2023 to 9.5 (USD Billion) by 2032. The acute bacterial skin and skin structure infection market CAGR (growth rate) is expected to be around 4.44% during the forecast period (2024 - 2032).

Key Acute Bacterial Skin and Skin Structure Infection Market Trends Highlighted

Antimicrobial resistance, the growing incidence of surgical site infections, and the expanding population of immunocompromised individuals with weakened immune systems are the most important market trends.

These developments are anticipated to present lucrative possibilities in the global market for acute bacterial skin and skin structure infections in the coming years. Furthermore, expanded research and development activities, as well as the development of innovative treatments and therapies, are expected to drive market expansion.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Acute Bacterial Skin and Skin Structure Infection Market Drivers

Growing Prevalence of Skin Infections

The increasing incidence of skin infections is a major factor driving the growth of the global acute bacterial skin and skin structure infection market. Skin infections are common worldwide, affecting individuals of all ages and socioeconomic backgrounds.

Various factors contribute to the rise in skin infections, including the emergence of antibiotic-resistant bacteria, the growing population of immunocompromised individuals, and the increasing prevalence of chronic diseases such as diabetes and obesity.

As the number of skin infections continues to rise, the demand for effective treatments, including antibiotics, antiseptics, and wound care products, is expected to increase, fueling the growth of the market.

The rising prevalence of skin infections is particularly concerning in developing countries, where access to healthcare and sanitation may be limited. In these regions, skin infections can lead to severe complications and even death.

The World Health Organization (WHO) estimates that skin infections account for approximately 10% of the global burden of disease, highlighting the significant impact of these infections on public health.

To address the growing burden of skin infections, governments and healthcare organizations are implementing various strategies to improve prevention and treatment.

These strategies include promoting hygiene practices, increasing access to antibiotics, and developing new and more effective treatments. The implementation of these strategies is expected to further drive the growth of the global acute bacterial skin and skin structure infection market in the coming years.

Rising Healthcare Expenditure

The increasing expenditure on healthcare is another key factor driving the growth of the global acute bacterial skin and skin structure infection market.

Healthcare spending has been rising steadily in recent years due to factors such as the aging population, the growing prevalence of chronic diseases, and the introduction of new and expensive medical technologies. As healthcare expenditure continues to rise, the demand for medical products and services, including those used to treat skin infections, is expected to increase.

The rising healthcare expenditure is particularly evident in emerging markets, where governments are investing heavily in improving healthcare infrastructure and access to medical care. This increased investment is leading to a growing demand for medical products and services, including those used to treat skin infections.

The growing demand for medical products and services in emerging markets is expected to contribute to the growth of the global acute bacterial skin and skin structure infection market in the coming years.

Technological Advancements

The rapid pace of technological advancements in the healthcare industry is also driving the growth of the global acute bacterial skin and skin structure infection market. Technological advancements are leading to the development of new and more effective treatments for skin infections, as well as improved diagnostic tools and devices.

These advancements are making it easier to diagnose and treat skin infections, which is leading to better patient outcomes and a reduced burden on the healthcare system.

One of the most significant technological advancements in the treatment of skin infections is the development of new antibiotics. New antibiotics are being developed that are more effective against resistant bacteria, which is making it easier to treat skin infections that were once difficult to cure.

Additionally, new diagnostic tools and devices are being developed that can help to identify the cause of a skin infection more quickly and accurately, which is leading to more targeted and effective treatment.

Acute Bacterial Skin and Skin Structure Infection Market Segment Insights:

Acute Bacterial Skin and Skin Structure Infection Infection Type Insights

The global acute bacterial skin and skin structure infection market is segmented by Infection Type into Cellulitis, Erysipelas, Impetigo, Folliculitis, and Abscess. Among these, Cellulitis held the largest market share of around 39.5% in 2023, and the market is expected to grow at a CAGR of 4.2% during the forecast period 2024-2032.

The global acute bacterial skin and skin structure infection market for Cellulitis was valued at around USD 2.54 billion in 2023 and is expected to reach around USD 3.61 billion by 2032. The high prevalence of Cellulitis is attributed to factors such as the increasing incidence of skin injuries, surgical site infections, and the growing number of immunocompromised patients.

Erysipelas, another common type of skin infection, accounted for a market share of approximately 22.1% in 2023. The market for Erysipelas is expected to grow at a CAGR of 4.5% during the forecast period, reaching a value of around USD 2.14 billion by 2032.

Impetigo, a contagious skin infection caused by bacteria, held a market share of around 17.2% in 2023. The market for Impetigo is anticipated to grow at a CAGR of 4.3% during the forecast period, reaching a value of around USD 1.63 billion by 2032. Folliculitis, a skin infection that affects hair follicles, accounted for a market share of approximately 12.7% in 2023.

The market for Folliculitis is expected to grow at a CAGR of 4.1% during the forecast period, reaching a value of around USD 1.21 billion by 2032. Abscess, a collection of pus beneath the skin, held a market share of around 8.5% in 2023.

The market for Abscess is anticipated to grow at a CAGR of 4.0% during the forecast period, reaching a value of around USD 803.4 million by 2032. The growth of the market for acute bacterial skin and skin structure infections is driven by factors such as the rising prevalence of skin infections, increasing awareness of hygiene practices, and the growing adoption of advanced treatment options.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Acute Bacterial Skin and Skin Structure Infection Pathogen Insights

Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas aeruginosa, Enterobacteriaceae, and Anaerobes are the major pathogens responsible for causing acute bacterial skin and skin structure infections (BSI).

Staphylococcus aureus is the most common cause of ABSSSI, accounting for approximately 30% of cases. Streptococcus pyogenes is the second most common cause, accounting for approximately 20% of cases.

Pseudomonas aeruginosa is a common cause of ABSSSI in hospitalized patients and immunocompromised individuals. Enterobacteriaceae and Anaerobes are less common causes of ABSSSI, but they can cause severe infections in certain populations.

The increasing prevalence of skin and soft tissue infections, the rise in antibiotic resistance, and the growing demand for advanced treatment options are major factors driving the growth of the market.

Acute Bacterial Skin and Skin Structure Infection Treatment Setting Insights

The Treatment Setting segment of the global acute bacterial skin and skin structure infection market is segmented into Outpatient, Inpatient, and Emergency Departments. Among these segments, the Outpatient segment is expected to witness the fastest growth during the forecast period (2024-2032).

The increasing preference for outpatient care due to lower costs, shorter wait times, and greater convenience is driving the growth of this segment. In 2023, the Outpatient segment accounted for a significant share of the global acute bacterial skin and skin structure infection market revenue.

The growth of this segment can be attributed to the rising prevalence of skin and skin structure infections (SSSIs) and the increasing adoption of advanced treatment modalities in outpatient settings.

Outpatient clinics and ambulatory surgical centers are becoming increasingly popular for the treatment of SSSIs due to their ability to provide timely and effective care. The Inpatient segment is also expected to experience steady growth during the forecast period. The increasing severity of SSSIs and the need for prolonged hospitalization are contributing to the growth of this segment.

Hospitals provide a controlled environment for patients with severe infections to receive intensive care and monitoring. The Emergency Department segment is expected to account for a smaller share of the global acute bacterial skin and skin structure infection market revenue.

However, this segment is expected to witness moderate growth during the forecast period due to the increasing number of patients seeking emergency care for SSSIs. Emergency departments play a crucial role in providing initial assessment and treatment to patients with skin infections before they are referred to appropriate outpatient or inpatient settings.

Acute Bacterial Skin and Skin Structure Infection Mechanism of Action Insights

The Mechanism of Action segment of the global acute bacterial skin and skin structure infection market is segmented into Penicillins, Cephalosporins, Macrolides, Lincosamides, and Fluoroquinolones. The Penicillins segment accounted for the largest share of the market in 2023 and is projected to continue to dominate the market over the forecast period.

The Cephalosporins segment is expected to grow at the highest CAGR over the forecast period. The global acute bacterial skin and skin structure infection market is driven by the increasing prevalence of skin and soft tissue infections, the rising demand for effective and safe antibiotics, and the growing awareness of the importance of skin health.

The market is also supported by the development of new and innovative antibiotics, as well as the increasing availability of generic drugs. The global acute bacterial skin and skin structure infection market is a highly competitive market with a number of major players.

The key players in the market include Pfizer, GlaxoSmithKline, Johnson Johnson, Merck Co., and Novartis. These companies are investing heavily in research and development to develop new and innovative antibiotics, as well as to improve the efficacy and safety of existing antibiotics.

Acute Bacterial Skin and Skin Structure Infection Route of Administration Insights

The Global Acute Bacterial Skin and Skin Structure Infection (ABSSSI) Market is segmented into Oral, Intravenous, and Topical based on the Route of Administration.

The market for Oral administration is expected to account for the largest share of the global ABSSSI Market in 2023, owing to the ease of administration and cost-effectiveness of oral medications. The Intravenous route of administration is preferred in severe cases where rapid drug delivery is required.

The Topical route of administration is suitable for localized infections and is less likely to cause systemic side effects.

The global acute bacterial skin and skin structure infection market for Oral administration is projected to grow at a CAGR of 4.2% during the forecast period (2024-2032).

The Intravenous route of administration is expected to grow at a CAGR of 4.5% during the forecast period. The Topical route of administration is projected to grow at a CAGR of 4.8% during the forecast period.

Acute Bacterial Skin and Skin Structure Infection Regional Insights

The global acute bacterial skin and skin structure infection market is segmented into North America, Europe, APAC, South America, and MEA. The North American region is expected to hold the largest market share due to the high prevalence of skin infections and the increasing adoption of advanced treatment options.

The European region is also expected to contribute significantly to the market growth, driven by the rising geriatric population and the increasing demand for advanced wound care products. The APAC region is expected to witness the fastest growth rate due to the increasing healthcare expenditure and the growing awareness about skin infections.

The South American and MEA regions are also expected to contribute to the market growth, albeit at a slower pace.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Acute Bacterial Skin and Skin Structure Infection Market Key Players and Competitive Insights:

Major players in the acute bacterial skin and skin structure infection market are constantly engaged in research and development activities to enhance their product offerings and gain a competitive edge. Strategic collaborations and partnerships are also prevalent as companies seek to expand their geographic reach and access new markets.

The acute bacterial skin and skin structure infection market is characterized by a diverse range of players, including multinational pharmaceutical companies, generic drug manufacturers, and specialty pharmaceutical companies focused on dermatology.

Leading acute bacterial skin and skin structure infection market players are investing in innovative technologies, such as novel drug delivery systems and targeted therapies, to address unmet medical needs and improve patient outcomes.

The acute bacterial skin and skin structure infection market development pipeline is robust, with several promising candidates in various stages of clinical development. These advancements are expected to further shape the competitive landscape and drive market growth in the coming years.

Pfizer, a leading player in the acute bacterial skin and skin structure infection market, has a strong portfolio of antibiotics, including Zithromax and Vibramycin, which are widely used to treat bacterial skin infections. The company's focus on research and development has resulted in the development of new antibiotics, such as Sivextro, which has demonstrated efficacy against a broad spectrum of bacteria.

Pfizer's global presence and strong distribution network enable it to reach a wide range of patients and healthcare providers. The company's commitment to innovation and patient care positions it well to maintain its leadership position in the acute bacterial skin and skin structure infection market.

Merck, a global pharmaceutical company, is another major competitor in the acute bacterial skin and skin structure infection market. The company's antibiotic portfolio includes Cubicin, which is used to treat severe skin and skin structure infections caused by Gram-positive bacteria.

Merck has also developed innovative technologies, such as its LipidRescue™ technology, which enhances the delivery of antibiotics to the site of infection. The company's strong research capabilities and commitment to developing new treatments for unmet medical needs make it a formidable competitor in the acute bacterial skin and skin structure infection market.

Merck's global reach and extensive healthcare partnerships allow it to effectively distribute its products and reach a broad patient population.

Key Companies in the Acute Bacterial Skin and Skin Structure Infection Market Include:

• Amryt Pharma


• CTI BioPharma


• Aralez Pharmaceuticals


• Bayer AG


• AN2 Therapeutics


• Almirall, S.A.


• Alliance Pharma


• Evotec


• GlaxoSmithKline PLC


• BiomX


• Cidara Therapeutics


• Hikma Pharmaceuticals


• Cipla


• Dermavant Sciences


• AstraZeneca


• Galderma

Acute Bacterial Skin and Skin Structure Infection Market Developments

Recent news and developments in the market include:

New drug approvals: In 2023, the FDA approved a new antibiotic, omadacycline, for the treatment of ABSSSI. This drug is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including those that are resistant to other antibiotics.

Increasing prevalence of ABSSSI: The prevalence of ABSSSI is increasing worldwide due to factors such as the rise of antibiotic resistance and the growing population of immunocompromised individuals. This is creating a need for new and effective treatments for ABSSSI.

Growing demand for home healthcare: The demand for home healthcare services is growing as more and more patients are being treated at home. This is creating a need for new and innovative ways to deliver ABSSSI treatments in the home setting.

Acute Bacterial Skin and Skin Structure Infection Market Segmentation

• Cellulitis


• Erysipelas


• Impetigo


• Folliculitis


• Abscess

• Staphylococcus aureus


• Streptococcus pyogenes


• Pseudomonas aeruginosa


• Enterobacteriaceae


• Anaerobes

• Outpatient


• Inpatient


• Emergency Department

• Penicillins


• Cephalosporins


• Macrolides


• Lincosamides


• Fluoroquinolones

• Oral


• Intravenous


• Topical

• North America


• Europe


• South America


• Asia Pacific


• Middle East and Africa